443-33-4

Usage

Uses

Used in Chemical Synthesis:
2-Chloro-6-fluorobenzaldoxime is used as an intermediate in the preparation of arenecarboxylic acids, which are essential building blocks in the synthesis of various organic compounds and pharmaceuticals. Its unique structure allows for further functionalization and modification, making it a valuable component in the development of new molecules with specific properties and applications.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2-Chloro-6-fluorobenzaldoxime is utilized as a key intermediate for the synthesis of various drug candidates. Its unique structural features enable the development of novel compounds with potential therapeutic applications, such as antibiotics, anti-inflammatory agents, and anticancer drugs.
Used in Agrochemical Industry:
2-Chloro-6-fluorobenzaldoxime also finds application in the agrochemical industry, where it is used as a starting material for the synthesis of various agrochemicals, including pesticides and herbicides. Its chemical properties make it suitable for the development of compounds with enhanced efficacy and selectivity, contributing to more effective and environmentally friendly agricultural practices.
Used in Dye and Pigment Industry:
In the dye and pigment industry, 2-Chloro-6-fluorobenzaldoxime is employed as a precursor for the synthesis of various dyes and pigments. Its unique structure allows for the creation of colorants with specific properties, such as improved color strength, lightfastness, and resistance to various environmental factors.
Used in Material Science:
2-Chloro-6-fluorobenzaldoxime is also utilized in the field of material science, where it serves as a building block for the development of novel materials with specific properties. These materials can be used in various applications, such as in the production of advanced polymers, coatings, and adhesives with improved performance characteristics.

InChI:InChI=1/C7H5ClFNO/c8-6-2-1-3-7(9)5(6)4-10-11/h1-4,11H

Upstream product

• 387-45-1 2-chloro-6-fluorobenzaldehyde 
• 443-83-4 2-chloro-6-fluorotoluene 

Downstream Products

• 51088-25-6 2-chloro-6-fluoro-N-hydroxybenzene-1-carbonimidoyl chloride 
• 40126-00-9 2-Chlor-6-fluor-benzonitriloxid 
• 75781-59-8 C₇H₄ClFNO 
• 75781-60-1 C₇H₄ClFNO 
• 668-45-1 2-chloro-6-fluorobenzonitrile 
• 83817-51-0 ethyl 3-(2-chloro-6-fluorophenyl)-5-methylisoxazole-4-carboxylate 
• 1391026-03-1 Prop-2-ynyl 3-(2-chloro-6-fluorophenyl)-5-methylisoxazole-4-carboxylate 
• 1391026-19-9 (1-(2-morpholino-2-oxoethyl)-1H-1,2,3-triazol-4-yl)methyl 3-(2-chloro-6-fluorophenyl)-5-methylisoxazole-4-caroboxylate 
• 1391026-20-2 (1-benzyl-1H-1,2,3-triazol-4-yl)methyl 3-(2-chloro-6-fluorophenyl)-5-methylisoxazole-4-carboxylate 
• 69399-79-7 3-(2-chloro-6-fluorophenyl)-5-methylisoxazole-4-carbonyl chloride 
• 3919-74-2 3-(2-chloro-6-flourophenyl)-5-methyl-isoxazole-4-carboxylic acid 
• 66073-54-9 2-chloro-6-fluoro-benzamide 
• 387-45-1 2-chloro-6-fluorobenzaldehyde 

Relevant academic research and scientific papers

HCl-mediated cascade cyclocondensation of oxygenated arylacetic acids with arylaldehydes: one-pot synthesis of 1-arylisoquinolines

In this paper, a concise, open-vessel synthesis of 1-arylisoquinolines is describedviaHCl-mediated intermolecular cyclocondensation of oxygenated arylacetic acids with arylaldehydes in the presence of NH2OH and alcoholic solvents under mild and one-pot reaction conditions. A plausible mechanism is proposed and discussed herein. In the overall reaction process, only water was generated as the byproduct. Various environmentally friendly reaction conditions are investigated for convenient transformationviathe (4C + 1C + 1N) annulation. This protocol provides a highly effective ring closureviathe formations of one carbon-carbon (C-C) bond, two carbon-nitrogen (C-N) bonds and one carbon-oxygen (C-O) bond.

Synthesis, Crystal Structure, and Herbicidal Activity of 3-(2-Chloro-6-fuorophenyl)-4-(2-oxooxazolidine-3-carbonyl)-5-methylisoxazole

ABSTRACT A novel N-aroyl diketone derivative, 3-(2-chloro-6-fluorophenyl)-4-(2-oxooxazolidine-3-carbonyl)-5-methylisoxazole (C14H10ClFN2O4, Mr=324.69), was designed via fragment analysis and coupling strategy that led to highly potent and bio-selective herbicide. The title compound was prepared by a multistep-reaction, including nucleophilic addition and N-acylation reaction using 2-chloro-6-fluorobenzaldehyde as the starting materials in 83.4% yield. The product was characterized by infrared, proton nuclear magnetic resonance, Carbon-13 nuclear magnetic resonance, human resource management system, and X-ray diffraction. The title compound crystallized in the monoclinic system, space group P21/n with a=10.7119(4) ?, b=17.5875(7) ?, c=11.5151(7) ?, b=100.927(2)°, Z=8, V=2870.0(2) ?3, F(000)=1328, Dc=1.503 Mg/m3, crystal size: 0.130 × 0.120 ×0.100 mm. The herbicidal activity was tested against the gramineous weed Echinochloa crus-galli and broadleaf Abutilon juncea.

Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis

Farnesoid X receptor (FXR) plays a key role in bile acid homeostasis, inflammation, fibrosis, and metabolism of lipid and glucose and becomes a promising therapeutic target for nonalcoholic steatohepatitis (NASH) or other FXR-dependent diseases. The phase III trial results of obeticholic acid demonstrate that the FXR agonists emerge as a promising intervention in patients with NASH and fibrosis, but this bile acid-derived FXR agonist brings severe pruritus and an elevated risk of cardiovascular disease for patients. Herein, we reported our efforts in the discovery of a series of non-bile acid FXR agonists, and 36 compounds were designed and synthesized based on the structure-based drug design and structural optimization strategies. Particularly, compound 42 is a highly potent and selective FXR agonist, along with good pharmacokinetic profiles, high liver distribution, and preferable in vivo efficacy, indicating that it is a potential candidate for the treatment of NASH or other FXR-dependent diseases.

HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS

The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): (I), wherein L1, A, X1, X2, R1, R2, and R3 are described herein.

Synthesis of new coumarin tethered isoxazolines as potential anticancer agents

A series of new coumarin tethered isoxazolines (7a-l) were synthesized and evaluated for their cytotoxic potency against human melanoma cancer cell line (UACC 903) as well as fibroblast normal cell line (FF2441). Preliminary results revealed that some of these coumarin tethered isoxazolines 7b, 7c, 7f and 7j exhibited significant antiproliferative effect against human melanoma cancer (UACC 903) with IC50 values of 8.8, 10.5, 9.2 and 4.5 μM respectively. However, compound 7c was non-toxic to normal human cells at the tested concentration. Further, we have chosen compound 7c to check its efficacy in Ehrlich Ascites Carcinoma animal model in-vivo for its antitumor and antiangiogenic properties. Our lead compound significantly reduced the cell viability, body weight, ascites volume and downregulated the formation of neovasculature such as regression of tumor volume. The present study indicates the scope of developing into potent anticancer drug in near future.

AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF A7-NICOTINIC ACETYLCHOLINE RECEPTORS

The present invention relates to novel aminobenzisoxazole compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of ot7-nAChR, and methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering the compound or composition to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom.

IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION

The present invention relates to compounds of the general formula (I), and the pharmaceutically acceptable salt or solvate thereof, as anti-inflammatory and immunomodulatory agents.

Synthesis of 1,2,3-triazole substituted isoxazoles via copper (I) catalyzed cycloaddition

The synthesis of a series of 3,5-disubstituted isoxazole-4-carboxylic esters containing N-substituted 1,2,3-triazoles (V) starting from various benzaldehydes (I) is reported. Benzaldehydes undergo oximation with hydroxylamine hydrosulfate. Later, chlorination followed by condensation with methylacetoacetate and the hydrolysis of the resulting ester afforded respective carboxylic acid (II), which on chlorination with PCl5 gave the corresponding acid chlorides (III). The coraboxylic acid chlorides (III) on propargylation gave propargylic esters (IV) and these on click reaction gave the title compounds (V).

Ruthenium-catalyzed rearrangement of aldoximes to primary amides in water

The rearrangement of aldoximes to primary amides has been studied using the readily available arene-ruthenium(II) complex [RuCl2(η 6-C6Me6){P(NMe2)3}] (5 mol %) as catalyst. Reactions proceeded cleanly in pure water at 100 °C without the assistance of any cocatalyst, affording the desired amides in high yields (70-90%) after short reaction times (1-7 h). The process was operative with both aromatic, heteroaromatic, α,β-unsaturated, and aliphatic aldoximes and tolerated several functional groups. Reaction profiles and experiments using 18O-labeled water indicate that two different mechanisms are implicated in these transformations. In both of them, nitrile intermediates are initially formed by dehydration of the aldoximes. These intermediates are then hydrated to the corresponding amides by the action of a second molecule of aldoxime or water. A kinetic analysis of the rearrangement of benzaldoxime to benzamide is also discussed.

An alkynyliodide cycloaddition strategy for the construction of iodoisoxazoles

(Figure presented) The thermally promoted cycloaddition between alkynyliodides and nitrile oxides is reported. The process offers excellent regioselectivity and a broad scope with respect to both the iodoalkynes and chloro-oximes. Further functionalization of the highly decorated iodoisoxazole motifs can be achieved via Suzuki cross-coupling.